Recent News

• 03.30.2026 - Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026
• 03.26.2026 - Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient
• 03.17.2026 - Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance
• 03.04.2026 - Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
• 03.04.2026 - Can-Fite’s Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study

Recent Filings

• 03.26.2026 - EX-99.1 EX-99.1
• 03.26.2026 - 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
• 03.26.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.18.2026 - 3 Initial statement of beneficial ownership of securities
• 03.18.2026 - 3 Initial statement of beneficial ownership of securities
• 03.18.2026 - 3 Initial statement of beneficial ownership of securities
• 03.18.2026 - 3 Initial statement of beneficial ownership of securities
• 03.18.2026 - 3 Initial statement of beneficial ownership of securities
• 03.17.2026 - EX-99.1 EX-99.1
• 03.17.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]